Go Pro
TSE:CTX

Crescita Therapeutics Q4 2025 Earnings Report

Crescita Therapeutics logo
C$0.79 0.00 (0.00%)
As of 06/4/2026

Crescita Therapeutics EPS Results

Actual EPS
-C$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Crescita Therapeutics Revenue Results

Actual Revenue
$5.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Crescita Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 31, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Crescita Therapeutics Earnings Headlines

Congress Just Opened the Floodgates
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial technology framework in US history. JPMorgan, Citi, Bank of America and Wells Fargo are building a shared next generation payment network targeting 2027, and the DTCC just completed its first live production trades on the new system. Senior analyst Andy Howard breaks down the asset at the center of this shift in a free report.tc pixel
See More Crescita Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescita Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescita Therapeutics and other key companies, straight to your email.

About Crescita Therapeutics

Crescita Therapeutics (TSE:CTX) Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.

View Crescita Therapeutics Profile